Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)

NCT05846230 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05846230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05846230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 8, 2023
Completion date
March 31, 2027
Enrollment
268 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis